Pain and Inflammation as Mediators of Tofacitinib Treatment Effect on Fatigue in Patients with Ankylosing Spondylitis: A Mediation Analysis
Joseph Cappelleri
Rheumatology and therapy, 2023
View PDFchevron_right
Impact of Ixekizumab on Work Productivity in Patients with Ankylosing Spondylitis: Results from the COAST-V and COAST-W Trials at 52 Weeks
Helena Marzo-ortega
Rheumatology and Therapy, 2020
View PDFchevron_right
Identifying and Quantifying the Role of Inflammation in Pain Reduction for Patients With Psoriatic Arthritis Treated With Tofacitinib: A Mediation Analysis
Valderilio F Azevedo
Rheumatology and Therapy
View PDFchevron_right
Multicenter open-label study with infliximab in active ankylosing spondylitis over 28 weeks in daily practice
H. Haibel
Clinical and experimental rheumatology, 2008
View PDFchevron_right
The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis
Peter Taylor
RMD Open
View PDFchevron_right
Correlation of fatigue with other disease related and psychosocial factors in patients with rheumatoid arthritis treated with tocilizumab
Joan Dalmau Carolà
Medicine
View PDFchevron_right
Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs
Joel Kremer
Arthritis Research & Therapy, 2015
View PDFchevron_right
Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis
David Sandoval Jacobo
Rheumatology and Therapy, 2019
View PDFchevron_right
The impact of tocilizumab on physical function and quality of life in patients with rheumatoid arthritis: a systematic literature review and interpretation
Shatara Townes
Open Access Rheumatology: Research and Reviews, 2012
View PDFchevron_right
Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: Results from a randomized controlled study
Fred Dorey
Arthritis & Rheumatism, 2007
View PDFchevron_right
Effect of Tocilizumab on Fatigue and Bone Mineral Density in Patients with Rheumatoid Arthritis
Mahmoud Abu-shakra
The Israel Medical Association journal : IMAJ, 2018
View PDFchevron_right
Tofacitinib in Combination With Conventional Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient‐Reported Outcomes From a Phase III Randomized Controlled Trial
Joel Kremer
Arthritis Care & Research, 2017
View PDFchevron_right
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis
vibeke strand
Rheumatology (Oxford, England), 2016
View PDFchevron_right
Functional Assessment of Chronic Illness Therapy-Fatigue is a reliable and valid measure in patients with active ankylosing spondylitis
Joseph Cappelleri
Journal of Patient-Reported Outcomes, 2022
View PDFchevron_right
Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
Joel Kremer
New England Journal of Medicine, 2012
View PDFchevron_right
Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial
Xianwei Bu
Annals of the Rheumatic Diseases
View PDFchevron_right
THU0361 Prescription patterns of biological disease modifying drugs and biosimilars in ankylosing spondylitis – a collaboration between biological registers in the five nordic countries
Katerina Chatzidionysiou
Poster Presentations, 2017
View PDFchevron_right
Effect of secukinumab on patient-reported outcomes in patients with active ankylosing spondylitis: A Phase 3 randomized trial (MEASURE 1)
vibeke strand
Arthritis & rheumatology (Hoboken, N.J.), 2016
View PDFchevron_right
Evaluation of the patient acceptable symptom state as an outcome measure in patients with ankylosing spondylitis: Data from a randomized controlled trial
Alan Moore
Arthritis & Rheumatism, 2008
View PDFchevron_right
Tofacitinib in Combination with Conventional DMARDs in Patients with Active Rheumatoid Arthritis: PROs from a Phase 3 Randomized Controlled Trial
vibeke strand
Arthritis Care & Research, 2016
View PDFchevron_right
Indirect comparison of the effects of anti-TNF biological agents in patients with Ankylosing Spondylitis by means of a Mixed Treatment Comparison performed on efficacy data from published randomised, controlled trials
B. Laganà
Journal of Medical Economics, 2012
View PDFchevron_right
Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept
Wayne Tsuji
The Journal of rheumatology, 2008
View PDFchevron_right
Ixekizumab improves sleep and work productivity in patients with non-radiographic axial spondyloarthritis: results from the COAST-X trial at 52 weeks
Steven Lauzon
BMC Rheumatology
View PDFchevron_right
Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: An open, observational, extension study of a three-month, randomized, placebo-controlled trial
Joachim Listing
Arthritis & Rheumatism, 2003
View PDFchevron_right
Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol
vibeke strand
Rheumatology, 2010
View PDFchevron_right
Assessment of fatigue in Moroccan patients with ankylosing spondylitis
Yousra Yous
Clinical Rheumatology, 2010
View PDFchevron_right
Impact of TNF inhibitor medication on working ability in axial spondyloarthritis: an observational national registry-based cohort study
Markku J Kauppi
Rheumatology Advances in Practice, 2023
View PDFchevron_right
Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis
Jette Frederiksen
Annals of the Rheumatic Diseases, 2005
View PDFchevron_right
A Possible Correlation Among Different Disease Activity Parameters and Functional Status in Patients with Ankylosing Spondylitis
SALİHA EROĞLU DEMİR
Turkish Journal of Rheumatology, 2013
View PDFchevron_right
Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis
Alan Worsley, Ying He
BMC Musculoskeletal Disorders, 2013
View PDFchevron_right
Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: Results of a fifty-two-week, randomized, controlled study
arthur weaver
Arthritis and Rheumatism, 2005
View PDFchevron_right
Assessment of clinical efficacy and safety in a randomized double-blind study of etanercept and sulfasalazine in patients with ankylosing spondylitis from Eastern/Central Europe, Latin America, and Asia
Ruben Burgos-Vargas
Rheumatology international, 2016
View PDFchevron_right
European perspective on the management of rheumatoid arthritis: clinical utility of tofacitinib
Maria Kózka
Therapeutics and Clinical Risk Management, 2017
View PDFchevron_right
Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis
Orsolya Balogh
The European journal of health economics : HEPAC : health economics in prevention and care, 2014
View PDFchevron_right